Related references
Note: Only part of the references are listed.Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
Vlad Ratziu et al.
JOURNAL OF HEPATOLOGY (2023)
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH
Jun Xu et al.
HEPATOLOGY (2023)
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
Quentin M. Anstee et al.
HEPATOLOGY (2023)
Mechanisms of pruritus in cholestasis: understanding and treating the itch
Ulrich Beuers et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2023)
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial
Arun J. Sanyal et al.
NATURE MEDICINE (2023)
FXR and NASH: an avenue for tissue-specific regulation
Zakiyah Henry et al.
HEPATOLOGY COMMUNICATIONS (2023)
Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers
Islam R. R. Younis et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2023)
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis
Arun J. Sanyal et al.
JOURNAL OF HEPATOLOGY (2023)
Modulation of alkaline phosphatase levels by obeticholic acid in clinical trials and cultured human hepatocytes
Alan Bonder et al.
JOURNAL OF HEPATOLOGY (2023)
FXR: structures, biology, and drug development for NASH and fibrosis diseases
Si-yu Tian et al.
ACTA PHARMACOLOGICA SINICA (2022)
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis
Zobair M. Younossi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study
Mary E. Rinella et al.
JOURNAL OF HEPATOLOGY (2022)
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
Naim Alkhouri et al.
JOURNAL OF HEPATOLOGY (2022)
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
Vlad Ratziu et al.
JOURNAL OF HEPATOLOGY (2022)
Breakthroughs in therapies for NASH and remaining challenges
Vlad Ratziu et al.
JOURNAL OF HEPATOLOGY (2022)
Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world
Linda Henry et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
Current therapies and new developments in NASH
Jean-Francois Dufour et al.
GUT (2022)
Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH
Nikolai V. V. Naoumov et al.
JOURNAL OF HEPATOLOGY (2022)
Recent advances on FXR-targeting therapeutics
Katrin Panzitt et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2022)
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
Stephen A. Harrison et al.
NATURE MEDICINE (2022)
Farnesoid X receptor activation by the novel agonist TC-100 (3?, 7?, 11?-Trihydroxy-6?-ethyl-5?-cholan-24-oic Acid) preserves the intestinal barrier integrity and promotes intestinal microbial reshaping in a mouse model of obstructed bile acid flow
M. Marzano et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States
Zobair M. Younossi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease
Stefan Traussnigg et al.
WIENER KLINISCHE WOCHENSCHRIFT (2021)
The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model
Philipp Schwabl et al.
BIOMEDICINES (2021)
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
Rohit Loomba et al.
HEPATOLOGY (2021)
Research in brief
Holly Baker
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Rohit Loomba et al.
CELL (2021)
FXR agonists for NASH: How are they different and what difference do they make?
Claus Kremoser
JOURNAL OF HEPATOLOGY (2021)
Therapeutic aspects of bile acid signalling in the gut-liver axis
Benedikt Simbrunner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
FXR in liver physiology: Multiple faces to regulate liver metabolism
Katrin Panzitt et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2021)
Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities
Richard Radun et al.
SEMINARS IN LIVER DISEASE (2021)
Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers
Yujin Wang et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2021)
Farnesoid X receptor (FXR): Structures and ligands
Longying Jiang et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2021)
Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development
Justin D. Schumacher et al.
HEPATOLOGY (2020)
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
Marcos Pedrosa et al.
CONTEMPORARY CLINICAL TRIALS (2020)
Mechanisms of Fibrosis Development in NASH
Robert F. Schwabe et al.
GASTROENTEROLOGY (2020)
Cilofexor, a NonsteroidalFXRAgonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
Keyur Patel et al.
HEPATOLOGY (2020)
Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
Mohammad Shadab Siddiqui et al.
JOURNAL OF HEPATOLOGY (2020)
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis
Donatella Chianelli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
Jean-Francois Dufour et al.
GUT (2020)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
Michael K. Badman et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction
Ping An et al.
LIVER INTERNATIONAL (2020)
FXR Isoforms Control Different Metabolic Functions in Liver Cells via Binding to Speci fi c DNA Motifs
Jose Miguel Ramos Pittol et al.
GASTROENTEROLOGY (2020)
Nidufexor, a non-bile acid FXR agonist, decreases ALT and hepatic fat fraction in patients with NASH after 12 weeks dosing
Richard Aspinall et al.
JOURNAL OF HEPATOLOGY (2020)
Chemokines in Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis
Xiongfeng Pan et al.
FRONTIERS IN IMMUNOLOGY (2020)
FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human
Emma Henriksson et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Obeticholic acid may increase the risk of gallstone formation in susceptible patients
Samer Al-Dury et al.
JOURNAL OF HEPATOLOGY (2019)
FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis
Marcel Sorribas et al.
JOURNAL OF HEPATOLOGY (2019)
Molecular tuning of farnesoid X receptor partial agonism
Daniel Merk et al.
NATURE COMMUNICATIONS (2019)
The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease
Dan-Ying Zhang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
Jonathan D. Roth et al.
SCIENTIFIC REPORTS (2019)
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
Vlad Ratziu et al.
CONTEMPORARY CLINICAL TRIALS (2019)
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development
Juliette Mouries et al.
JOURNAL OF HEPATOLOGY (2019)
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
Paul J. Pockros et al.
LIVER INTERNATIONAL (2019)
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Reenam S. Khan et al.
HEPATOLOGY (2019)
Obeticholic acid: towards first approval for NASH
Mohammed Eslam et al.
LANCET (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Identification of a bilirubin receptor that may mediate a component of cholestatic itch
James Meixiong et al.
ELIFE (2019)
Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents
Eloy D. Hernandez et al.
HEPATOLOGY COMMUNICATIONS (2019)
An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers
Amani Al-Khaifi et al.
GASTROENTEROLOGY (2018)
The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines
Gideon M. Hirschfield et al.
GUT (2018)
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
Scott L. Friedman et al.
HEPATOLOGY (2018)
FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver
Romeo Papazyan et al.
JOURNAL OF LIPID RESEARCH (2018)
Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman et al.
NATURE MEDICINE (2018)
Progress and challenges of selective Farnesoid X Receptor modulation
Vittoria Massafra et al.
PHARMACOLOGY & THERAPEUTICS (2018)
FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid
Elliot S. Friedman et al.
GASTROENTEROLOGY (2018)
Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
Ludovico Abenavoli et al.
PHARMACEUTICALS (2018)
Molecular Magnetic Resonance Imaging Accurately Measures the Antifibrotic Effect of EDP-305 a Novel Farnesoid X Receptor Agonist
Derek J. Erstad et al.
HEPATOLOGY COMMUNICATIONS (2018)
Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction
Wenxuan Xu et al.
FEBS JOURNAL (2017)
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
Auvro R. Mridha et al.
JOURNAL OF HEPATOLOGY (2017)
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction
Philipp Schwabl et al.
JOURNAL OF HEPATOLOGY (2017)
Hepatic stellate cells as key target in liver fibrosis
Takaaki Higashi et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Prognostic and Mechanistic Potential of Progesterone Sulfates in Intrahepatic Cholestasis of Pregnancy and Pruritus Gravidarum
Shadi Abu-Hayyeh et al.
HEPATOLOGY (2016)
Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties
Olaf Kinzel et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers
R. Pencek et al.
DIABETES OBESITY & METABOLISM (2016)
Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats
Maria Ubeda et al.
JOURNAL OF HEPATOLOGY (2016)
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders
Roberto Pellicciari et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
Len Verbeke et al.
SCIENTIFIC REPORTS (2016)
Activation of farnesoid X receptor downregulates monocyte chemoattractant protein-1 in murine macrophage
Liangpeng Li et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Bile Acids as Hormones: The FXR-FGF15/19 Pathway
Steven A. Kliewer et al.
DIGESTIVE DISEASES (2015)
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Paul Angulo et al.
GASTROENTEROLOGY (2015)
Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia
Michael J. Genin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Sungsoon Fang et al.
NATURE MEDICINE (2015)
A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity
Dong-Hyun Kim et al.
EMBO JOURNAL (2015)
Obeticholic Acid, a Farnesoid X Receptor Agonist, Improves Portal Hypertension by Two Distinct Pathways in Cirrhotic Rats
Len Verbeke et al.
HEPATOLOGY (2014)
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Sunder Mudaliar et al.
GASTROENTEROLOGY (2013)
Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology
Ingmar Mederacke et al.
NATURE COMMUNICATIONS (2013)
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
Luciano Adorini et al.
DRUG DISCOVERY TODAY (2012)
Activation of the Farnesoid X Receptor Induces Hepatic Expression and Secretion of Fibroblast Growth Factor 21
Holly A. Cyphert et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR
Anna C. Calkin et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modifications
Jongsook Kim Kemper
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2011)
The Bile Acid Membrane Receptor TGR5: A Valuable Metabolic Target
Thijs W. H. Pols et al.
DIGESTIVE DISEASES (2011)
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease
Raffaella M. Gadaleta et al.
GUT (2011)
Lysophosphatidic Acid Is a Potential Mediator of Cholestatic Pruritus
Andreas E. Kremer et al.
GASTROENTEROLOGY (2010)
Genome-Wide Tissue-Specific Farnesoid X Receptor Binding in Mouse Liver and Intestine
Ann M. Thomas et al.
HEPATOLOGY (2010)
Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist
Giovanni Rizzo et al.
MOLECULAR PHARMACOLOGY (2010)
Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts
Peter Fickert et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
FXR Promotes Endothelial Cell Motility Through Coordinated Regulation of FAK and MMP-9
Amitava Das et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Farnesoid X Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat Diet
Bo Kong et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Philippe Lefebvre et al.
PHYSIOLOGICAL REVIEWS (2009)
FXR: a metabolic regulator and cell protector
Yan-Dong Wang et al.
CELL RESEARCH (2008)
Farnesoid X Receptor Antagonizes Nuclear Factor κB in Hepatic Inflammatory Response
Yan-Dong Wang et al.
HEPATOLOGY (2008)
Farnesoid X receptor ligands inhibit vascular smooth muscle cell inflammation and migration
Yoyo T. Y. Li et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Back door modulation of the farnesoid X receptor: Design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives
Roberto Pellicciari et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Farnesoid X receptor is essential for normal glucose homeostasis
K Ma et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor
T Inagaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Activation of the nuclear receptor FXR induces fibrinogen expression: a new role for bile acid signaling
AM Anisfeld et al.
JOURNAL OF LIPID RESEARCH (2005)
Structural basis for bile acid binding and activation of the nuclear receptor FXR
LZ Mi et al.
MOLECULAR CELL (2003)
A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR
M Downes et al.
MOLECULAR CELL (2003)
Bile acids induce the expression of the human peroxisome proliferator-activated receptor α gene via activation of the farnesoid X receptor
IP Torra et al.
MOLECULAR ENDOCRINOLOGY (2003)
Identification of membrane-type receptor for bile acids (M-BAR)
T Maruyama et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity
R Pellicciari et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis
CJ Sinal et al.
CELL (2000)
A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis
B Goodwin et al.
MOLECULAR CELL (2000)
Identification of a chemical tool for the orphan nuclear receptor FXR
PR Maloney et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
